Pure Storage vs BIO-TECHNE Corp — how do they compare? Pure Storage trades at $154.49 (market cap $50.17B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Pure Storage is far larger — about 4.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Pure Storage pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pure Storage for 3 Days and BIO-TECHNE Corp for 64 Days on average.
| P | TECH | |
|---|---|---|
Market Cap | $50.17B | $11.36B |
Volume | 5,733,762 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $154.49 | $72.61 |
52-Week Low | $56.99 | $43.31 |
Typical Hold Time | 3 Days | 64 Days |
Enterprise Value | $49.39B | $11.39B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.
Read more on P →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →